Publications
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the USPublications
Explore the expertise, insights, and perspectives from OPEN Health that help transform complexity into clarity across today’s healthcare landscape.